Background: We attempted to test the hypothesis that the direct renin inhibitor aliskiren can improve diastolic dysfunction, glucose, and insulin metabolism (GIM) in overweight and obese hypertensive patients. Methods and results: Seventy-eight hypertensive patients were divided into two groups: 38 treated with aliskiren for six months, and 40 treated without aliskiren but with only traditional anti-hypertensive therapy, as controls. Doppler mitral flow velocity patterns were assessed before and after aliskiren during a six-month period. GIM (three-hour intravenous glucose tolerance test) was measured after four to six weeks of washout and six months of treatment. The mitral E/A ratio increased from 0.65 ± 0.11 to 0.75 ± 0.19. None of the indexes changed in the control group. In the control group, GIM parameters, fasting glucose levels (5.3 ± 0.9 to 6.0 ± 1.5 mmol/l; p = 0.003), fasting insulin levels (121 ± 121 to 189 ± 228 pmol/l; p = 0.03), and most other relevant metabolic measures (p < 0.05 for all) significantly worsened. Aliskiren did not affect GIM. In the control group LVM/height was not affected (119 ± 12 to 120 ± 17 g/m; p = 0.8), whereas aliskiren significantly reduced LVM/height (120 ± 13 to 111 ± 19 g/m; p = 0.04). Conclusions: Optimal target BP was achieved in the group as a whole and in both obese patient groups, while benefits to cardiac structure were of a smaller magnitude. In high-risk, overweight/obese patients with hypertension, traditional therapy provides significantly greater BP-versus aliskiren-lowering throughout the 24-hour dosing interval. Therefore in obese, hypertensive individuals, adequate and similar blood pressure control was achieved with aliskiren; however, the aliskiren group and not the control group was associated with a more favorable GIM profile and led to a significant regression of LVM; overall aliskiren-based treatment offers sustained control of PRA. Cardiology Unit, University ''Federico II'' Italy
Introduction
Hypertension is a major public health issue that is currently under-recognized and undertreated. The idea of reducing blood pressure by blocking the renin−angiotensin− aldosterone system at its origin by direct inhibition of renin has existed for more than 30 years, and angiotensin-converting enzyme (ACE) inhibitors and angiotensin II (Ang II) receptor blockers have shown efficacy for improved cardiovascular outcomes in hypertensive patients. 1, 2 Although left ventricular (LV) systolic dysfunction occurs only infrequently, diastolic dysfunction is a commonly observed cardiovascular manifestation even in the absence of ischemic heart diseases in hypertensive patients. 3 The pathogenesis of LV diastolic dysfunction is not fully clarified, but myocardial fibrosis is one of the most important mechanisms for diastolic dysfunction. 4 Activation of the local renin−angiotensin system is likely to contribute to the development of myocardial fibrosis as its importance has been demonstrated in a number of animal models of LV diastolic dysfunction. 5, 6 The renin−angiotensin system is certainly upregulated in hypertensives, and locally produced Ang II might well facilitate myocardial fibrosis. 7 Thus, we might expect Ang II type 1A receptor blockade (ARB) to work toward cardio protection by reducing myocardial fibrosis in hypertensive patients. LV diastolic filling is noninvasively assessable by analyzing pulsed Doppler mitral flow velocity patterns. Even LV chamber stiffness (KLV) may be assessed from the measurement of the deceleration time of the early diastolic mitral filling wave. 8 The metabolic effects of antihypertensive drugs still remain the key aspect of the management of metabolic syndrome and a point of debate concerning 'first-choice' drugs in hypertension treatment. Although the outcome benefits of ACE inhibitors and ATII receptor antagonists in diabetic patients are well established, 9 the first-line therapy of metabolic syndrome remains controversial.
Aliskiren is the first in a new class of direct renin inhibitors (DRI) and has been approved by the United States Food and Drug Administration and the European Medicines Agency for the treatment of hypertension at once-daily oral doses of 150 mg and 300 mg. By directly targeting the renin enzyme, aliskiren inhibits the renin system at the point of activation, blocking the conversion of angiotensinogen to Ang I and decreasing levels of Ang I and Ang II. 10 Aliskiren decreases plasma renin activity (PRA) by approximately 50-80% in patients with hypertension 11, 12 and provides similar reductions when administered in combination with drugs known to increase PRA such as ACE inhibitors, ARBs or the diuretic as hydrochlorothiazide (HCT). 12, 13 Elevated PRA has been identified as an independent predictor of morbidity and mortality (p = 0.0025) in a large-scale trial of 4300 patients with congestive heart failure. 14 Moreover, in a study of 699 patients with congestive heart failure, PRA levels were independently associated with cardiovascular events despite the continued use of ACE inhibitors and ARBs. 15 However, the full clinical implications of the different effects of antihypertensive agents on PRA are not yet known. 16 An association between hyperinsulinemia and LV hypertrophy (H) was previously described, 17 but little has been written about the association between changes in insulin sensitivity and changes in LVM with antihypertensive therapy. In this study, we hypothesized that the effects of antihypertensive therapy on glucose and insulin metabolism (GIM) are associated with their effects on LV mass (M) regression. We tested this hypothesis in a group of obese hypertensives by using agents with similar blood pressure (BP)-lowering effects but known discrepant effects on insulin sensitivity. Thus, we repeatedly assessed LV diastolic filling in hypertensive patients to test the hypothesis that the direct renin inhibitor aliskiren can improve diastolic dysfunction in these patients.
Methods

Subjects and study protocol
Candidates of the study were 78 patients aged ≥ 60 years with mild to moderate hypertension, defined as mean sitting diastolic BP (msDBP) ≥ 90 mmHg and < 110 mmHg.
They were among those regularly followed in the outpatient clinic of Federico II University Hospital of Naples, Italy. The main exclusion criteria included severe hypertension (msDBP ≥ 110 mmHg and/or mean sitting systolic BP (msSBP) ≥ 180 mmHg); secondary hypertension; type 1 or type 2 diabetes mellitus with fasting glycosylated hemoglobin (HbA1c) > 9%; history of severe cerebrovascular or cardiovascular disease; and any condition that may affect the evaluation of efficacy or safety data, or alter the absorption, distribution, metabolism or excretion of study drugs.
Prior to the study, they were referred to an echocardiography laboratory to examine LV function, and only those with abnormal LV diastolic dysfunction but with normal LV systolic function were selected. None of the patients with ischemic electrocardiography (ECG) changes (≥ 0.1 mV, horizontal S-T shift) were detected in the Master's two-step exercise test. The criterium for LV diastolic dysfunction was a mitral E/A ratio of less than 0.8 or greater than 1.5. None showed a mitral E/A ratio greater than 1.5, and consequently only those with a mitral E/A ratio of less than 0.8 were selected. LV systolic function was judged normal if an ejection fraction (EF) was 50% or greater. A total of 78 patients met the criteria (54 men and 24 women, mean age 67 years). The 78 patients were randomly divided into one of two subsets: 1) administering aliskiren for six months (aliskiren group), and 2) administering no medicines affecting the renin−angiotensin system such as ARB, ACI inhibitor or spironolactone (control group). Hypertension was treated by the administration of β blockers or calcium channel blockers in any of the control group patients if necessary. The aliskiren group consisted of 38 patients (27 men and 11 women; mean age 66 years). The other 30 patients (19 men and 11 women; mean age 67 years) (not including 10 patients, eight men and two women, who dropped out of the study for personal reasons) belonged to the control group. All subjects gave informed consent, and the local committee on human research approved the study protocol. Aliskiren was administered 150 or 300 mg/day for six months to all of the patients of the aliskiren group; medication did not change during the observation term. Biomarker, hemodynamic, and echo parameters were obtained at entry and repeated after six months.
Assessments
BP measurements
Clinic BP was evaluated prior the study, then every three weeks for Weeks 3-21 and at Week 26 during the activecontrolled-treatment period. BP was assessed weekly during the four-week post-active-controlled-treatment period. BP was measured at trough (24 ± three hours after dosing) using a sphygmomanometer, and three sitting BP measurements, taken at one-two-minute intervals, were averaged to give the mean value for that visit. Changes in msSBP and msDBP during the 26-week active-controlled-treatment period were determined in the intent-to-treat (ITT) population, and were analyzed for non-inferiority (and superiority if non-inferiority was achieved) of aliskiren-based therapy versus control group-based therapy. During the post-activecontrolled-treatment period, mean changes in msSBP and msDBP from the post-treatment baseline (Week 26) to Week 30 endpoint were analyzed for treatment superiority. BP changes were analyzed using an analysis of covariance model with treatment and region as factors and baseline BP as covariate. Analysis of BP changes with aliskiren or traditional antihypertensive therapy at the Week 12 endpoint was carried out according to subgroup of baseline PRA; the low PRA level was defined as ≤ 0.65 ng/ml/h and medium/ high PRA level was defined as > 0.65 ng/ml/h. 18 
Biomarkers
Biomarkers were evaluated prior the study and at Week 26. In addition, PRA and plasma renin concentration (PRC) were assessed during the post-active-controlled-treatment period (Weeks 26 and 30). PRA was measured by means of radioimmunoassay of generated Ang I. PRC and plasma aldosterone concentrations were measured by immunochemiluminescence. Samples for the measurement of biomarkers were collected after the patient had been in the supine position for a minimum of 20 minutes. Samples were collected between 07.00 and 10.00 hours (h) at the first visit, and ± one h of the first collection time at subsequent visits. In order to avoid cryoactivation of plasma prorenin, blood samples for the determination of PRA, PRC, and aldosterone were collected into ethylenediaminetetraacetic acid (EDTA) tubes and stored at ambient temperature prior to processing. Within 10 minutes of collection, blood was centrifuged at room temperature at 2500 g for 10 minutes. Plasma samples were frozen immediately at −20°C or lower prior to shipping at −70°C. Samples were shipped the day of collection; samples that could not be shipped the day of collection were stored at −70°C and shipped the next working day. Serum samples were stored and shipped in the same manner as plasma samples. After randomization and four to six weeks of placebo washout, the patients underwent an intravenous glucose tolerance test (IVGTT); these tests were repeated after six months of treatment.
Echocardiographic study
Two-dimensional (2D) echo-targeted M-mode and Doppler recordings were obtained for each patient as described. 19 The LVM index was calculated by dividing the LVM by body surface area. 19 Pulsed Doppler mitral flow velocity pattern was recorded at the mitral tip by 2D echo guidance to provide measurements for quantitative analysis. In addition to the ratio of the peak early diastolic filling velocity to the peak velocity at atrial contraction (E/A ratio), the deceleration time (TDEC) of the early diastolic filling wave was measured to estimate the LV stiffness constant (KLV) according to the following equation: 8 KLV=(0.08:TDEC)2 (mmHg/ml).
Metabolic investigations
Insulin and glucose responses to IVGTT were evaluated as previously described. 20 Each participant was instructed to adhere to a diet rich in carbohydrates (at least 250 g/d) and to refrain from either strenuous physical exercise or inactivity for ≥ three days before the investigation. Patients were admitted to the hospital the morning of the study after an overnight fast (10 to 12 h). Samples for baseline insulin and glucose levels were drawn at 15, 20, 25, and 30 minutes after the intravenous catheter insertion. IVGTT was then performed with a standardized bolus injection of 300 mg of glucose per kilogram of body weight (in a 50% solution given over one minute). Plasma glucose and insulin levels were drawn after two, three, four, five, six, eight, 10, 12, 14, 16, 19, 22, 25, 30, 40 , 50, 60, 70, 80, 90, 100, 120, 140, 160, and 180 minutes. Plasma glucose levels (millimoles per liter) were measured by the glucose oxidase method using a Beckmann analyzer (Beckmann Instruments). Plasma insulin levels (picomoles per liter) were measured by radioimmunoassay using a Pharmacia insulin kit. Fasting insulin and glucose levels were defined as the average of levels drawn before glucose infusion. On the basis of previous findings, 21 the following metabolic indices were used to quantitate GIM: fasting insulin level, peak insulin level after infusion, insulin level after 90 minutes, insulin integration over 180 minutes of IVGTT (total insulin integration area), fasting glucose level, peak glucose level, glucose levels after 90 minutes, and glucose integration over 180 minutes of IVGTT (total glucose integration area).
Safety and tolerability
Adverse events (AEs) were monitored and recorded at each study visit. Other safety assessments, which included measurement of vital signs, physical examination, 12-lead electrocardiogram and monitoring of hematology, blood chemistry, and urine test values, were performed at regular intervals throughout the study.
Statistical analysis
Results are expressed as mean ± SD. Comparisons between the two groups were analyzed by using the unpaired Student's t test. Differences between data before and after aliskiren were assessed by using the paired Student's t test. Simple linear regression analysis was used to examine the relationship of aliskiren-induced changes in the LV chamber stiffness constant. Correlation coefficients were calculated by linear regression analysis. A p value of less than 0.05 was considered statistically significant.
All biomarker data are presented as geometric means and 95% confidence intervals (CI). The 95% CIs were calculated by anti-log transformation of the 95% CIs of logtransformed biomarker measurements. Table 1 shows demographic and baseline patients with biomarker data. The study population consisted of 68 overweight and obese, hypertensive, nondiabetic subjects. One patient in the aliskiren group was lost to follow-up, and the results of the remaining 37 patients (26 men and 11 women) are reported. Only peak insulin levels were significantly different between the groups at baseline. This was an isolated finding that was considered of no clinical significance given the high variability in peak insulin measurements, especially in insulin-resistant individuals. As shown in Table 2 , aliskiren and no aliskiren therapy led to a significant and similar reduction in both systolic BP (from 151 to 129 mm Hg and from 151 to 127 mm Hg for the aliskiren group and control group, respectively; p = 0.002) and diastolic BP (from 98 to 81 mm Hg and from 98 to 82 mm Hg, respectively; p = 0.002). Aliskiren-treated patients showed no significant changes in any of the metabolic parameters, but they did have a significant reduction in LVM/height (from 120 to 111 g/m; p = 0.04). No aliskiren-treated patients showed a significant deterioration in most of the metabolic parameters, including fasting glucose levels (p = 0.003), fasting insulin levels (p = 0.03), and peak glucose (p = 0.005). No significant changes in LVM/height (from 119 to 120 g/m; p = 0.19) occurred in the control group. Aliskiren-based therapy reduced PRA by 63% from baseline to the Week 26 endpoint, whereas no aliskirenbased therapy increased PRA by 143% at this time point. Mean PCR at baseline was 14.9 and 14.4 mU/l in aliskiren-and no aliskiren-treatment groups, respectively ( Table 1) . PRC increased significantly (p < 0.05) from baseline to the Week 26 endpoint with both the aliskiren-(+224%) and no aliskiren-(+145%) based regimens during the treatment period. In patients who continued active treatment, there was little change in either PRA or PRC levels during the four-week post-active-controlled-treatment period (Figure 1 ). In patients who continued aliskiren-based therapy, PRA had decreased by 68% from pre-treatment baseline (Week 0) at the end of the four-week post-active-controlledtreatment period (Week 30; p < 0.05; Figure 1 (a) ), whereas PRA increased by 215% in patients who continued no aliskiren-based therapy (p < 0.05).
Results
In patients who switched from either aliskiren or no aliskiren-based therapy to placebo, PRC decreased rapidly, returning to pre-treatment baseline two weeks after stopping treatment (Week 28; Figure 1 (b) ). Despite the rapid decrease in PRC in patients who switched from aliskiren basedtherapy to placebo, PRA levels increased only gradually during the post-active-controlled treatment period and remained 52% below pretreatment baseline four weeks after stopping aliskiren-based therapy (Week 30; p < 0.05; Figure 1 (a)); this equates to a maintenance of 89% of the PRAlowering effect. In contrast, PRA rapidly decreased over the post-active-controlled treatment period in patients who stopped the no aliskiren-based therapy, returning to pretreatment baseline levels two weeks after stopping treatment (Week 28). Baseline plasma aldosterone values were in the low normal range (geometric mean 156.7 and 179.2 pmol/l for aliskiren and no aliskiren-group, respectively), and did not change significantly with either treatment regimen during the study. Parameters of echocardiography at baseline and after 26 weeks of treatment are presented in Table 3 . The interventricular wall thickness changed only in the aliskiren group (p < 0.05), posterior wall thickness and LV diastolic dimension did not change significantly. Additionally, LVMI decreased from 114 ± 9 to 103 ± 8 on aliskiren (9.6%, p < 0.01) and slightly decreased in the no aliskiren group (from 115 ± 9 to 107 ± 9, 4.6%, NS). The mitral E/A ratio increased from 0.65 ± 0.11 to 0.75 ± 0.19 (p < 0.01) following aliskiren treatment. Other parameters of diastolic function remained unchanged in both groups, with a tendency of isovolumetric relaxation time to decrease.
Discussion
LVH regression with antihypertensive therapy is only partially related to the hemodynamic effects of BP lowering. 22 ACE inhibitors seem to promote LVH regression more effectively than other antihypertensive agents due to their beneficial effects on nonhemodynamic factors, such as the renin−angiotensin system, the adrenergic nervous system, and growth and metabolic factors, including insulin. 23, 24 In this study, we assessed the effects of treatment with the direct renin inhibitor aliskiren and no medicines affecting the renin angiotensin system such as ARB, ACI inhibitor or spironolactone (control group) on LVM and GIM in a group of insulin-resistant, obese, hypertensive subjects. We found a similar reduction in BP but different effects on LVM and GIM. Aliskiren had a neutral effect on insulin sensitivity and caused a significant reduction in LVM, whereas no aliskiren therapy had a negative or deleterious effect on GIM and caused no reduction in LVM. These findings support the hypothesis that the effects of antihypertensive therapy on GIM parallel the effects of the therapy on LVM in obese, hypertensive, insulin-resistant individuals. Since the association between increased LVM and insulin resistance in rare genetic disorders was first described, several studies have confirmed this association in obese and hypertensive populations. 25, 26 Obesity has been associated with subclinical LV contractile dysfunction, even in the presence of a normal EF. The extent to which subclinical LV dysfunction is reversible in obese versus non-obese individuals is unknown. According to O'Brien et al. 27 the percentage of improvement in contractile function was less in patients with greater body mass index (BMI) in the setting of hypertensive heart disease with normal EF, following treatment with antihypertensive therapy. Our results and the finding of a significant inverse correlation between BMI and LV diastolic parameters in obese subjects only indicate that overweight plays a relevant role in the development of diastolic dysfunction, which appears to be a primary feature of cardiomyopathy associated with obesity. The design and methods of the present study do not allow an assessment of mechanisms involved in the development of diastolic dysfunction in obesity. By directly targeting the renin enzyme, aliskiren inhibits the renin system at the point of activation, blocking the conversion of angiotensinogen to Ang I and decreasing levels of Ang I and Ang II, thereby reducing interstitial collagen deposition and fibrosis. The indirect benefits of optimizing hemodynamics include improving LV filling and reducing blood pressure. Insulin may lead to myocardial hypertrophy and an increase in LVM through a variety of pathways; an important part of this increase seems to be an antiproteolytic effect in the heart. McNulty et al. 28 studied the effects of insulin on myocardial protein synthesis, degradation, and net balance in 11 individuals and observed a significant antiproteolytic effect of insulin on the heart. This reduction in protein degradation occurred without any change in cardiac work. Several clinical studies have shown that the administration of ACE inhibitors results in increased insulin-stimulated glucose disposal in diabetics or hypertensive individuals. The mechanisms of this action were initially thought to be exclusively related to an improvement in capillary blood flow. ACE inhibitors increase bradykinin levels through the inhibition of kininase II, which causes vasodilation and augmented capillary blood flow and thereby increases the delivery of insulin and glucose to skeletal muscle. 29 Andersson et al. 30 suggested that patients treated with fosinopril had a significantly greater reduction in LV wall thickness, which correlated with enhanced skeletal muscle blood flow, suggesting that in nonobese hypertensive individuals, impaired peripheral blood flow and consequent increased afterload may mediate the association between insulin resistance and LVH. Our study showed several positive metabolic effects of aliskiren compared with no aliskiren therapy, including decrease of hyperinsulinemia and hyperglycemia, factors contributing to metabolic syndrome. Besides, these changes were observed in an unselected patient population and do not definitely have prognostic implications; they could indicate that use of aliskiren could be favorable in correction of risk factors other than hypertension and possibly could prevent diabetes development or delay its manifestation in predisposed patients. Andersen et al. report biomarker data from a long-term study to compare the efficacy, safety, and tolerability of treatment regimens based on aliskiren and the ACE inhibitor ramipril at the maximum commonly used dose in patients with mild to moderate hypertension. 18 Our results show that aliskiren-based therapy provided long-term control of PRA. At the end of the active-controlled-treatment period (Week 26), PRC levels were increased with both aliskiren-based (+224%) and no aliskiren-based (+145%) treatments because of loss of Ang II-mediated feedback inhibition of renal renin release. Despite the increase in PRC, aliskirenbased therapy lowered PRA by 63% (whereas no aliskirenbased therapy significantly increased PRA by +143%), demonstrating that aliskiren-based therapy provides longterm control of PRA. Previous clinical studies have also demonstrated effective control of PRA when aliskiren is used in combination with HCT, 12 as well as during coadministration with the ACE inhibitor ramipril 13 or the ARB valsartan, 31 drug classes that also increase PRA. The findings of the present study suggest that the increase in PRC that occurs during aliskiren-based therapy does not lead to increases in PRA when treatment is stopped.
During the post-active-controlled-treatment period, BP changes in patients who stopped active treatment paralleled changes in PRA. Thus, most of the BP-lowering effects of no aliskiren-based treatment were lost one week after stopping therapy, so median BP values were no longer below the target BP of 140/90 mm Hg one week after stopping treatment. By contrast, median BP values did not exceed 140/90 mm Hg four weeks after stopping aliskiren-based therapy. Indeed, msSBP/msDBP-lowering efficacy was maintained at 73%/83% one week after stopping aliskirenbased therapy compared with only 55%/66% after stopping no aliskiren-based therapy. The gradual return of BP toward baseline levels observed after stopping aliskiren-based therapy reflected the prolonged effects of aliskiren on PRA. The long-term suppression of PRA after aliskiren withdrawal might be explained by renal accumulation of aliskiren, which has been shown to be up to 50-fold in animal studies. 32 In vitro studies indicate that aliskiren is taken up by renin secretory cells and binds intracellularly to stored renin, thus inhibiting renin activity of this enzyme before its secretion. 33 This effect, and the gradual partitioning of aliskiren from the kidneys after stopping treatment, may explain the persistent effects of aliskiren on PRA beyond the half-life of the drug.
The prolonged PRA suppression might reduce BP fluctuations following missed doses and may be seen as clinically beneficial. There are no data to support the idea that such long-term suppression of PRA might have deleterious effects. However, PRA is only one marker of renin−angiotensin−aldosterone system activity, and the clinical effects of its suppression are at present unknown.
The findings of the present study provide no evidence that responses to aliskiren may be poor or absent in patients with suppressed baseline PRA levels, as has previously been suggested. 34 In a previous study of aliskiren in 569 patients with mild-to-moderate hypertension, regression analysis showed no significant correlation between baseline PRA and SBP change following eight weeks' treatment with once-daily aliskiren 150-600 mg, 35 suggesting that the ability of aliskiren to lower BP is effectively independent of baseline PRA. It is important to note the limitations of the present study. First, the clinical implications of the different effects of treatment on markers such as PRA and PRC are not yet known. Studies with previous-generation, peptide-like renin inhibitors showed that some commercial assays may overestimate renin inhibition when a renin inhibitor is present; the antibody-trapping assay should therefore be used to measure PRA in the presence of peptide-like renin inhibitors. However, there is no evidence to suggest that the same artifact is seen with a structurally distinct, nonpeptide such as aliskiren. Second, although the validity of this study may be limited by the small study sample and by the fact that only 55% of our patients had LVH at baseline, as defined as LVM/height >110 g/m 2 for women and >134g/m 2 for men, 19 the results may be consistent in accordance with the available literature, which demonstrates the differential effects of ß-blockers or calcium channel blockers and ACE inhibitors on insulin resistance and LVM. 36 
Conclusions
In conclusion, aliskiren-based therapy provided reductions in BP and PRA that were sustained over six months of treatment. The antihypertensive effect of aliskiren monotherapy was essentially independent of baseline PRA. Nearly 90% of the PRA-lowering efficacy was maintained four weeks after stopping aliskiren treatment, suggesting that the inhibitory effects of aliskiren on PRA extended beyond the elimination half-life of the drug. These results indicate that aliskiren-based treatment offers sustained control of PRA and effective BP lowering during long-term therapy in patients with hypertension. We concluded that in obese, hypertensive individuals, aliskiren and other therapy with ß-blockers or calcium channel blockers led to a similar reduction in BP. However, aliskiren was associated with a more favorable metabolic profile and a significant LVM reduction and, therefore, may be a preferable agent in this population.
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